Formulary
Lusutrombopag: Indications, Dosing, Side Effects and Interactions
Lusutrombopag is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
MedNext Academy | 3 min read
Lusutrombopag: Indications, Dosing, Side Effects and Interactions
Lusutrombopag is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
Drug action
Lusutrombopag is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
Indications and dose
**Thrombocytopenia [in patients with chronic liver disease undergoing invasive procedures] (under expert supervision)**
- **Adult** (By Mouth): 3 mg once daily for 7 days, treatment to be started at least 8 days before procedure; in clinical trials procedures were carried out between 9 to 14 days after starting lusutrombopag.
Cautions
Administration before laparotomy, thoracotomy, open-heart surgery, craniotomy, or excision of organs (no clinical experience); body-weight less than 45kg (limited information available); history of splenectomy (no clinical experience); risk factors for thromboembolism Cautions, further information Body-weight less than 45kg Monitor platelet count approximately 5 days after the first dose and as necessary thereafter; stop treatment if the platelet count reaches 50x10 9 /litre or more and has increased 20x10 9 /litre from baseline.
Side effects
Common or very common Headache; nausea; rash Frequency not known Embolism and thrombosis
Pregnancy
Manufacturer advises avoid-no information available.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises caution in severe impairment (limited information available)-monitor platelet count approximately 5 days after the first dose and as necessary thereafter. Stop treatment if the platelet count reaches 50x10 9 /litre or more and has increased 20x10 9 /litre from baseline.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Lusutrombopag in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

